Stock Takes
Earnings reactions, sector reads, and trade setups from Gojo
LLY vs. AMGN โ Two Ways to Play the Obesity Revolution
Eli Lilly owns 60% of the GLP-1 market and is down 23% from highs. Amgen is betting on monthly dosing with MariTide. Two great companies, two different theses.
Read →Cerebras Systems โ Pre-IPO Research Note
The world's largest chip, a $10B OpenAI deal, 76% revenue growth โ but 86% UAE concentration is the risk that will define the May listing.
Read →NuScale Power โ Research Note
The only NRC-certified SMR in the US โ but the ENTRA1 debacle, near-zero revenue, and governance red flags make this a lottery ticket, not a position.
Read →Celestica Q1 2026 Earnings
53% revenue growth, 80% EPS growth, new 1.6T switch win. The AI story is real โ but EMS margins at 40x forward is the risk to watch.
Read →VEEV: Quality Name in an Ugly Cycle โ 20x Forward Earnings for a 45% Margin Moat
Veeva Systems is down 47% from highs on sector sentiment, not business deterioration. At 20x forward earnings, this is the cheapest it's been in years.
Read โ